Catherine Duggan1, Rosana Risques, Catherine Alfano, Donna Prunkard, Ikuyo Imayama, Sarah Holte, Kathy Baumgartner, Rick Baumgartner, Leslie Bernstein, Rachel Ballard-Barbash, Peter Rabinovitch, Anne McTiernan. 1. Affiliations of authors: Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA (CD, II, SH, AM); Department of Pathology (RR, DP, PR), Department of Epidemiology, School of Public Health (AM), and Department of Medicine, School of Medicine, University of Washington, Seattle, WA (RR, DP, PR, AM); Office of Cancer Survivorship (CA) and Applied Research Program (RB-B), National Cancer Institute/National Institutes of Health, Bethesda, MD; Department of Epidemiology & Population Health, University of Louisville, Louisville, KY (KB, RB); Department of Cancer Etiology, City of Hope National Medical Center, Duarte, CA (LB).
Abstract
BACKGROUND: Progressive telomere shortening with cell division is a hallmark of aging. Short telomeres are associated with increased cancer risk, but there are conflicting reports about telomere length and mortality in breast cancer survivors. METHODS: We measured peripheral blood leukocyte telomere length at two time points in women enrolled in a multiethnic, prospective cohort of stage I to stage IIIA breast cancer survivors diagnosed between 1995 and 1999 with a median follow-up of 11.2 years. We evaluated associations between telomere length measured at mean 6 (baseline; LTL0; n = 611) and 30 months (LTL30; n = 478) after diagnosis and the change between those time points (n = 478), with breast cancer-specific and all-cause mortality using Cox proportional hazards models adjusted for possible confounders. Statistical tests were two-sided. RESULTS: There were 135 deaths, of which 74 were due to breast cancer. Neither baseline nor 30-month telomere length was associated with either all-cause or breast cancer-specific mortality (LTL0: hazard ratio [HR] = 0.83, 95% confidence interval [CI] = 0.67 to 1.02; HR = 0.88; 95% CI = 0.67 to 1.15; LTL30: HR = 0.78, 95% CI = 0.59 to 1.05; HR = 0.86; 95% = CI = 0.58 to 1.26, respectively). However, participants whose telomeres shortened between baseline and 30 months were at a statistically significantly increased risk of breast cancer-specific (HR = 3.03; 95% CI = 1.11 to 8.18) and all-cause mortality (HR = 2.38; 95% CI = 1.28 to 4.39) compared with participants whose telomeres lengthened. When follow-up was censored at 5-years after diagnosis, LTL0 (HR = 0.66; 95% CI = 0.45 to 0.96), LTL30 (HR = 0.51; 95% CI = 0.29 to 0.92), and change in telomere length (HR = 3.45; 95% CI = 1.11 to 10.75) were statistically significantly associated with all-cause mortality. CONCLUSIONS: Telomere shortening was associated with increased risk of breast cancer-specific and all-cause mortality, suggesting that change in blood telomere length over time could be a biomarker of prognosis. Research on determinants of telomere length and change is needed.
BACKGROUND: Progressive telomere shortening with cell division is a hallmark of aging. Short telomeres are associated with increased cancer risk, but there are conflicting reports about telomere length and mortality in breast cancer survivors. METHODS: We measured peripheral blood leukocyte telomere length at two time points in women enrolled in a multiethnic, prospective cohort of stage I to stage IIIA breast cancer survivors diagnosed between 1995 and 1999 with a median follow-up of 11.2 years. We evaluated associations between telomere length measured at mean 6 (baseline; LTL0; n = 611) and 30 months (LTL30; n = 478) after diagnosis and the change between those time points (n = 478), with breast cancer-specific and all-cause mortality using Cox proportional hazards models adjusted for possible confounders. Statistical tests were two-sided. RESULTS: There were 135 deaths, of which 74 were due to breast cancer. Neither baseline nor 30-month telomere length was associated with either all-cause or breast cancer-specific mortality (LTL0: hazard ratio [HR] = 0.83, 95% confidence interval [CI] = 0.67 to 1.02; HR = 0.88; 95% CI = 0.67 to 1.15; LTL30: HR = 0.78, 95% CI = 0.59 to 1.05; HR = 0.86; 95% = CI = 0.58 to 1.26, respectively). However, participants whose telomeres shortened between baseline and 30 months were at a statistically significantly increased risk of breast cancer-specific (HR = 3.03; 95% CI = 1.11 to 8.18) and all-cause mortality (HR = 2.38; 95% CI = 1.28 to 4.39) compared with participants whose telomeres lengthened. When follow-up was censored at 5-years after diagnosis, LTL0 (HR = 0.66; 95% CI = 0.45 to 0.96), LTL30 (HR = 0.51; 95% CI = 0.29 to 0.92), and change in telomere length (HR = 3.45; 95% CI = 1.11 to 10.75) were statistically significantly associated with all-cause mortality. CONCLUSIONS: Telomere shortening was associated with increased risk of breast cancer-specific and all-cause mortality, suggesting that change in blood telomere length over time could be a biomarker of prognosis. Research on determinants of telomere length and change is needed.
Authors: Fabrizio d'Adda di Fagagna; Philip M Reaper; Lorena Clay-Farrace; Heike Fiegler; Philippa Carr; Thomas Von Zglinicki; Gabriele Saretzki; Nigel P Carter; Stephen P Jackson Journal: Nature Date: 2003-11-05 Impact factor: 49.962
Authors: Simon Verhulst; Abraham Aviv; Athanase Benetos; Gerald S Berenson; Jeremy D Kark Journal: Eur J Epidemiol Date: 2013-08-30 Impact factor: 8.082
Authors: Elissa S Epel; Elizabeth H Blackburn; Jue Lin; Firdaus S Dhabhar; Nancy E Adler; Jason D Morrow; Richard M Cawthon Journal: Proc Natl Acad Sci U S A Date: 2004-12-01 Impact factor: 11.205
Authors: Anne McTiernan; Kumar B Rajan; Shelley S Tworoger; Melinda Irwin; Leslie Bernstein; Richard Baumgartner; Frank Gilliland; Frank Z Stanczyk; Yutaka Yasui; Rachel Ballard-Barbash Journal: J Clin Oncol Date: 2003-05-15 Impact factor: 44.544
Authors: Xifeng Wu; Christopher I Amos; Yong Zhu; Hua Zhao; Barton H Grossman; Jerry W Shay; Sherry Luo; Waun Ki Hong; Margaret R Spitz Journal: J Natl Cancer Inst Date: 2003-08-20 Impact factor: 13.506
Authors: Belinda L Needham; Xu Wang; Judith E Carroll; Sharrelle Barber; Brisa N Sánchez; Teresa E Seeman; Ana V Diez Roux Journal: Psychoneuroendocrinology Date: 2018-12-07 Impact factor: 4.905
Authors: Catherine Duggan; Richard N Baumgartner; Kathy B Baumgartner; Leslie Bernstein; Stephanie George; Rachel Ballard; Marian L Neuhouser; Anne McTiernan Journal: Breast Cancer Res Treat Date: 2017-12-18 Impact factor: 4.872
Authors: Judith E Carroll; Stephanie Esquivel; Alyssa Goldberg; Teresa E Seeman; Rita B Effros; Jeffrey Dock; Richard Olmstead; Elizabeth C Breen; Michael R Irwin Journal: Sleep Date: 2016-03-01 Impact factor: 5.849
Authors: Eli Puterman; Alison Gemmill; Deborah Karasek; David Weir; Nancy E Adler; Aric A Prather; Elissa S Epel Journal: Proc Natl Acad Sci U S A Date: 2016-10-03 Impact factor: 11.205
Authors: Jennifer A Doherty; Laurie Grieshober; John R Houck; Matthew J Barnett; Jean De Dieu Tapsoba; Mark Thornquist; Ching-Yun Wang; Gary E Goodman; Chu Chen Journal: Cancer Epidemiol Biomarkers Prev Date: 2018-05-09 Impact factor: 4.254